Stockholders' Equity | 10. Stockholders’ Equity The changes in stockholders’ equity for the prior year comparable period are as follows: Additional Accumulated Common Stock Paid-in Treasury Stock Comprehensive Retained Shares Amount Capital Shares Amount Loss Earnings Total Balance at September 30, 2023 36,142,345 $ 36 $ 265,945 ( 5,433,045 ) $ ( 84,031 ) $ ( 10,458 ) $ ( 9,958 ) $ 161,533 Net income — — — — — — 1,907 1,907 Exercise of stock options, grants of restricted stock awards, and vesting of restricted stock units 59,471 — 127 — — — — 127 Taxes paid associated with net settlement of stock compensation awards ( 12,058 ) — ( 224 ) — — — — ( 224 ) Common stock repurchased — — — ( 68,692 ) ( 1,171 ) — — ( 1,171 ) Stock compensation expense — — 2,249 — — — — 2,249 Foreign currency translation and other — — — — — 958 — 958 Balance at December 31, 2023 36,189,758 $ 36 $ 268,096 ( 5,501,737 ) $ ( 85,202 ) $ ( 9,500 ) $ ( 8,051 ) $ 165,379 Stock Compensation Incentive Plans The Company maintains the Third Amended and Restated 2006 Omnibus Long-Term Incentive Plan (as amended, the LTIP) under which stock options, restricted stock units (RSUs), restricted stock awards (RSAs), and cash-settled stock appreciation rights (SARs) have been issued, and a private placement issuance related to the Company's acquisition of Bid4Assets. During the year ended September 30, 2024, the Company's shareholders approved an amendment to the LTIP to increase the number of shares of common stock from 20,300,000 to 22,800,000 , reserved for future issuance of awards under the LTIP. Vesting of RSUs and grants of RSAs count as 1.5x shares against the plan reserves. As of December 31, 2024 , 1,347,204 shares of common stock remained available for use. Stock Compensation Expense The table below presents the components of share-based compensation expense (in thousands): Three Months Ended December 31, 2024 2023 Equity-classified awards: Stock options $ 659 $ 500 RSUs & RSAs 2,772 1,749 Total Equity-classified award 3,431 2,249 Liability-classified awards: SARs — — Total stock compensation expense: $ 3,431 $ 2,249 The table below presents the components of share-based compensation expense by line-item within our Condensed Consolidated Statements of Operations (in thousands): Three Months Ended December 31, 2024 2023 Stock-compensation expense by function Technology and operations $ 551 $ 330 Sales and marketing 1,021 638 General and administrative 1,859 1,281 Total stock compensation expense: $ 3,431 $ 2,249 Stock Options and RSUs & RSAs The following table presents stock option and RSUs & RSAs grant activity: Three Months Ended December 31, 2024 Stock Options granted: Options containing only service conditions: 125,000 Weighted average exercise price $ 22.55 Weighted average grant date fair value $ 10.86 Options containing performance conditions: 125,000 Weighted average exercise price $ 22.55 Weighted average grant date fair value $ 10.86 RSUs & RSAs granted: RSUs & RSAs containing only service conditions: 304,519 Weighted average grant date fair value $ 23.55 RSUs & RSAs containing performance conditions: 304,521 Weighted average grant date fair value $ 23.55 The stock options and RSUs & RSAs containing only service conditions will vest over a four-year service period. The stock options and RSUs & RSAs containing performance conditions will vest upon the achievement of specified financial targets of the Company, a segment, or a division of a segment. Vesting is measured on the first day of each fiscal quarter over the three-year terms of the awards, starting with the first fiscal quarter after the first anniversary of the grant date. The range of assumptions used to determine the fair value of stock options using the Black-Scholes option-pricing model during the three months ended December 31, 2024, were as follows: Three Months Ended December 31, 2024 Dividend yield — Expected volatility 56.09 % - 57.96 % Risk-free interest rate 4.10 % - 4.10 % Expected term 4.4 - 5.0 years Share Repurchase Program From time to time, we may be authorized to repurchase issued and outstanding shares of our common stock under a share repurchase program approved by our Board of Directors. Share repurchases may be made through open market purchases, privately negotiated transactions or otherwise, at times and in such amounts as management deems appropriate. The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements and other market conditions. The repurchase program may be discontinued or suspended at any time and will be funded using our available cash. As of September 30, 2024, the Company had $ 7.6 million of remaining authorization to repurchase shares through December 31, 2025. On December 9, 2024, the Company's Board of Directors authorized the repurchase of up to an additional $ 10.0 million of the Company's outstanding shares of common stock through December 31, 2026. The Company made no repurchases during the three months ended December 31, 2024. As of December 31, 2024 , the Company had $ 17.6 million of remaining authorization to repurchase shares through December 31, 2026. Other Share Repurchases Separate from the share repurchase program, our stock incentive plans allow for participants to exercise stock options by surrendering shares of common stock equivalent in value to the exercise price due. Any shares surrendered to the Company in this manner are not available for future grant. During the three months ended December 31, 2024 , participants surrendered 582 shares of common stock in connection with the exercise of stock options. No shares were surrendered by participants in connection with the exercise of stock options during the three months ended December 31, 2023 . |